🧡 SAFFRON | #ESMO2026 | LBA6

EGFR blocked. MET escapes. SAFFRON closes the route!

Phase III (n=338): Osimertinib + savolitinib vs platinum–pemetrexed in MET-high, EGFR-mutated NSCLC after osimertinib.

📈 PFS: 7.6 vs 5.4 mo | HR 0.55
❤️ OS: 17.8 vs 12.9 mo | HR 0.68
⏳ DoR: 9.7 vs 5.7 mo

⚖️ Safety: Grade ≥3 treatment-related AEs 40% vs 52%, but serious AEs 41% vs 28% and discontinuations 14% vs 8%.

🎯 Verdict: Dual EGFR/MET blockade improves survival. MET selection is crucial; toxicity remains a trade-off.

📚 Ref: Lu S et al. SAFFRON, Phase III. ESMO 2026; LBA6.

@myESMO @OncoAlert @larvol

#MVOnco #LungCancer